I was in Silence Therapeutics(SLN) when they did a 50 to 1 share consolidation back in 2013. The share was around 4p/share and after consolidation £2.00/share. Over a short period of time the shares hit £3.74 and have since declined to £1.00/share. SLN just did not and have not followed up with good positive trial data and so the decline happened. I think we working with a different beast in VRP. The trial data has been strong, the path towards Phase III trails in COPD is… Read More
We've had our shares diluted here as a result of our recent placing and as time goes on we will have more.But this will only happen if the next trials are successful and if so, the sp will be far higher than it is now....having said that, if the trials fail, it won't matter how many shares we have as they'll all be worth jack. The Nasdaq listing is a placing but listed and funded on a different market and although the same, will run independent… Read More
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.